Alps Advisors Inc Eagle Pharmaceuticals, Inc. Transaction History

Alps Advisors Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	BUY	$41.26 - $51.35 $310,894 - $386,922	7,535 New	7,535 $335,000
Q2 2021 Aug 11, 2021	SELL	$36.86 - $44.5 $868,790 - $1.05 Million	-23,570 Closed	0 $0
Q1 2021 May 07, 2021	SELL	$40.32 - $50.97 $41,328 - $52,244	-1,025 Reduced 4.17%	23,570 $984,000
Q4 2020 Feb 03, 2021	BUY	$41.72 - $51.34 $1.03 Million - $1.26 Million	24,595 New	24,595 $1.15 Million
Q1 2020 May 06, 2020	SELL	$34.37 - $60.07 $203,229 - $355,193	-5,913 Closed	0 $0
Q4 2019 Feb 07, 2020	SELL	$54.32 - $64.31 $14,014 - $16,591	-258 Reduced 4.18%	5,913 $355,000
Q3 2019 Nov 04, 2019	SELL	$53.25 - $59.98 $94,731 - $106,704	-1,779 Reduced 22.38%	6,171 $349,000
Q2 2019 Aug 07, 2019	SELL	$46.61 - $58.45 $19,576 - $24,549	-420 Reduced 5.02%	7,950 $443,000
Q1 2019 May 01, 2019	BUY	$38.66 - $51.82 $62,319 - $83,533	1,612 Added 23.85%	8,370 $423,000
Q4 2018 Feb 04, 2019	SELL	$36.72 - $67.73 $12,337 - $22,757	-336 Reduced 4.74%	6,758 $272,000
Q3 2018 Oct 25, 2018	SELL	$66.65 - $83.86 $73,581 - $92,581	-1,104 Reduced 13.47%	7,094 $492,000
Q2 2018 Aug 02, 2018	BUY	$51.25 - $76.62 $46,330 - $69,264	904 Added 12.39%	8,198 $620,000
Q2 2018 Jul 25, 2018	SELL	$51.25 - $76.62 $66,010 - $98,686	-1,288 Reduced 15.01%	7,294 $390,000
Q1 2018 May 01, 2018	BUY	$52.16 - $66.86 $67,182 - $86,115	1,288 Added 17.66%	8,582 $452,000
Q4 2017 Feb 05, 2018	SELL	$49.6 - $60.87 $24,800 - $30,435	-500 Reduced 6.42%	7,294 $390,000
Q3 2017 Nov 03, 2017	BUY	$46.62 - $60.36 $363,356 - $470,445	7,794	7,794 $465,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.